Repligen (RGEN) CFO Jason Garland Sells $106K of Stock
CFO Jason Garland sold 733 shares of Repligen Corporation on June 25 under a planned sale.
Reviewed by automated data checks against the source filing. How we make and check alerts
Jason Garland, CFO at Repligen Corporation ($RGEN), sold 733 shares at an average price of $145, worth about $106,285, on June 25, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $RGEN is down 1.9% after 1 week, down 9.8% after 1 month and up 20.8% to date (from the $145.23 close on Jun 25, 2026).
RGEN
Repligen Corporation
Key Points
- Repligen CFO Jason Garland sold 733 shares on June 25, valued at $106,285, at an average price of $145 per share.
- Repligen Corporation trades around $147.01 with a market cap of $8.29 billion and a P/E ratio of 161.5.
- Analysts maintain a buy rating for Repligen, with price targets ranging from $142 to $220.
Get $RGEN trade alerts by text
We text you when insiders, Congress or big funds trade $RGEN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Repligen Corporation alert may contain errors. Disclosures
Repligen Corporation's CFO, Jason Garland, recently sold 733 shares of the company on June 25, 2026. The shares were sold at an average price of $145 each, amounting to a total transaction value of $106,285. This sale was part of a planned transaction, as disclosed in the filing.
Insider Buying and Selling at Repligen Corporation
In addition to Jason Garland's recent sale, several other insiders have made transactions. On May 14, 2026, Carrie Eglinton Manner, Nicolas Barthelemy, Martin Madaus, Glenn Muir, and Karen Dawes each bought shares of Repligen. These purchases were not part of any pre-arranged plan.
Repligen Corporation Stock Down 16.9%
Shares of NasdaqGS:RGEN traded near $147.01 on Saturday. Repligen Corporation, with a market cap of $8.29 billion, has a P/E ratio of 161.5 and a forward P/E of 57.7. The company's beta is 1.081, indicating moderate volatility compared to the market. The stock's 52-week range is between $100.99 and $175.77, with a 50-day moving average of $122.61 and a 200-day moving average of $138.61.
Analysts Set New Price Targets
Analysts continue to show confidence in Repligen with several maintaining buy ratings. On June 3, 2026, HSBC maintained its buy rating with a target price of $150. Wolfe Research assumed coverage with a buy rating and a target of $145 on June 2. RBC Capital reinstated its buy rating with a target of $160 on May 15. The consensus among 19 analysts is a buy recommendation, with an average target price of $176.11.
About Repligen Corporation
Repligen Corporation, headquartered in Waltham, Massachusetts, is a life sciences company that focuses on developing and commercializing bioprocessing technologies and systems. The company serves life sciences, biopharmaceutical, and diagnostics companies worldwide. Repligen's product offerings include chromatography systems, filtration products, and process analytics tools. The company was incorporated in 1981 and is led by CEO Olivier Loeillot.
Bottom Line
Jason Garland's recent sale of Repligen shares was part of a planned transaction, reflecting his personal financial strategy rather than a change in the company's outlook. Repligen remains a significant player in the healthcare sector, and its stock continues to be a topic of interest for analysts and investors alike. As always, insider transactions provide insight into executive actions but should be considered alongside other factors. Investors should remember that 13F filings and insider reports are historical and may not reflect current positions.
Related Filing Alerts
Source: Jason Garland's Form 4 filing on $RGEN (Jun 25, 2026). Find the original filing: RGEN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts